Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass

作者：Anastasilakis Athanasios D^*; Polyzos Stergios A; Makras Polyzois; Sakellariou Grigorios T; Bi**inas Ilias; Gkiomisi Athina; Delaroudis Sideris; Gerou Spyridon; Ballaouri Iris; Oikonomou Dimitrios; Papapoulos Socrates E

来源：Bone, 2012, 50(5): 1130-1134.

DOI：10.1016/j.bone.2012.02.006

• Acute phase response
• Bisphosphonates
• Lymphocytes
• Osteoporosis
• Zoledronate

An acute phase response (APR) is frequently observed in patients treated with intravenous (i.v.) zoledronate (ZOL). We aimed to define clinical and laboratory parameters that may predict ZOL-induced APR in women with low bone mass. Fifty-one postmenopausal women with low bone mass were given a single i.v. infusion of ZOL 5 mg. APR was clinically defined by the visual analog pain scale (VAS) for the musculoskeletal symptoms and body temperature. White blood cell count (WBC), leucocyte subpopulations. C-reactive protein (CRP), parathyroid hormone (PTH), 25-hydroxyvitamin D [25(OH)D], interleukins (IL)-1b and -6, tumor necrosis factor (TNF)alpha and interferon (IFN)gamma were measured before and 48 h following the infusion. Subsequently, patients were divided into those experiencing APR (APR+) or not (APR-). WBC, granulocytes, CRP, IL-1b and IL-6 were significantly increased, whereas lymphocytes, eosinophils, calcium, phosphate and 25(OH)D decreased 48 h after ZOL infusion. Twenty-eight of the 51 patients (54.9%) experienced an APR. APR+ patients were younger and had higher baseline lymphocytes compared to APR patients. There was no difference (p = 0.405) in the development of APR between treatment-naive patients (19/32, 59.4%) and patients previously treated with another oral nitrogen-containing bisphosphonate (9/19, 47.4%). In conclusion, our data suggest that pretreatment higher lymphocyte number increases the risk of APR while previous treatment with another nitrogen-containing bisphosphonate does no

• 出版日期2012-5